What's New
FTD in the News
AviadoBio CEO Emphasizes Collaborative Approach for Treating FTD
In October, U.K.-based gene therapy company AviadoBio, Ltd., and pharmaceutical company Astellas announced an exclusive option and…
Ferrer Doses First Participant in Phase 2 Study for PSP Treatment
Pharmaceutical company Ferrer announced that it has dosed the first participant in the PROSPER phase 2 clinical…
Persons with FTD Advisory Council Special Article: Holiday Madness
This article was written by a person with FTD to highlight the challenges of dealing with the…
All in the Family to end FTD: Colonial Electric’s Food for Thought Event Clears More than $1 Million Since Inception
AFTD Board alumnus, Steve Bellwoar, has raised more than $1 million to drive AFTD’s mission in memory…
A Conversation with a Neurologist at Denali Therapeutics
Recently, AFTD had a conversation with members of the Denali Therapeutics team, including Dr. Richard Tsai, to…
Thanks to Generosity of AFTD Ambassador, Californians Receive Crucial Financial Help
Terry Walter, an AFTD Ambassador in California and Nevada, has been a force for positive change and…
Young Caregiver Talks About Finding Support Amid FTD Journey on Dementia UK Podcast
A young FTD caregiver named Lizzie discussed the grief, uncertainty, and unexpected responsibilities she faced as she…
GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a…
A Conversation with Alector’s Vice President of Clinical Development
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had…
Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially…